WASHINGTON, April 13 (UPI) — The U.S. Food and Drug Administration says some inhalers used by asthma and chronic obstructive pulmonary disease patients are being phased out.
The FDA said seven metered-dose inhalers that contain ozone-depleting chlorofluorocarbons will be gradually removed from the U.S. marketplace. Alternative medications that do not contain the ozone-destroying chemicals are available, the federal agency said.
The affected products and their phase out schedule are:
– Tilade Inhaler (nedocromil), made by King Pharmaceuticals. Last date for sale: June 14.
– Alupent Inhalation Aerosol (metaproterenol), made by Boehringer Ingelheim Pharmaceuticals. Last date for sale: June 14.
– Azmacort Inhalation Aerosol (triamcinolone), made by Abbott Laboratories. Last date for sale: Dec. 31.
– Intal Inhaler (cromolyn), made by King Pharmaceuticals. Last date for sale: Dec. 31.
– Aerobid Inhaler System (flunisolide), made by Forest Laboratories. Last date for sale: June 30.
– Combivent Inhalation Aerosol (albuterol and ipratropium in combination), made by Boehringer Ingelheim Pharmaceuticals. Last date for sale: Dec. 31, 2013
– Maxair Autohaler (pirbuterol), made by Graceway Pharmaceuticals. Last date for sale: Dec. 31, 2013.
Patients using the inhalers scheduled to be phased out should talk to their health care professional about switching to one of several alternative treatments currently available, the FDA said.
Copyright 2010 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI’s prior written consent.